Pharmacological treatment of depression in patients with a primary brain tumour

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 5, 2013, Pages

  Rooney, Alasdair ^a   Grant, Robin ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT;

BRAIN TUMOR; CANCER GRADING; COGNITIVE DEFECT; COMORBIDITY; CONTROLLED CLINICAL TRIAL (TOPIC); DEATH; DEPRESSION; DEPRESSION ASSESSMENT; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG SAFETY; EMOTIONAL STRESS; FATIGUE; FOLLOW UP; HISTOLOGY; HUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEIZURE; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION; PSYCHOLOGY; PSYCHOLOGICAL ASPECT;

ANTIDEPRESSIVE AGENTS; BRAIN NEOPLASMS; DEPRESSION; HUMANS;

EID: 84891686085     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD006932.pub3     Document Type: Review

References (56)

1. Caudill JS, Brown PD, Cerhan JH, Rummans TA. Selective serotonin reuptake inhibitors, glioblastoma multiforme, and impact on toxicities and overall survival. The Mayo Clinic experience. American Journal of Clinical Oncology 2011;34:385-7.
2. Koval'chuk VV. Pharmacologic correction of psycho-emotive disorders in the rehabilitation of patients after removal of brain tumors [Original title unavailable (Russian)]. Voprosy Onkologii 2007;53(6):704-10.
3. Litofsky NS, Farace E, Anderson F Jr. Depression in patients with high-grade glioma: results of the Glioma Outcomes Project. Neurosurgery 2004;54(2):358-66.
4. Meyers CA, Weitzner MA, Valentine AD, Levin VA. Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. Journal of Clinical Oncology 1998;16(7):2522-7.
5. Morrow GR, Hickok JT, Roscoe JA, Raubertas RF, Andrews PLR, Flynn PJ. Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Centre Community Clinical Oncology Programme. Journal of Clinical Oncology 2003;21(24):4635-41.
6. Moss EL, Simpson JSA, Pelletier G, Forsyth P. An open-label study of the effects of bupropion SR on fatigue, depression and quality of life of mixed-site cancer patients and their partners. Psycho-oncology 2006;15:259-67.
7. Oyewumi LK, Lapierre YD. Efficacy of lithium in treating mood disorder occurring after brain stem injury. American Journal of Psychiatry 1981;138(1):110-2.
8. Rabey JM, Avrahami E. Unmasking of cerebellar tumours by amitriptyline in depressive patients. Journal of Neurology, Neurosurgery and Psychiatry 1985;48(3):291.
9. Shaw EG, Rosdhal R, D'Agostino Jr RB, Lovato J, Naughton MJ, Robbins ME, et al.Phase II study of donepezil in irradiated brain tumor patients: Effect on cognitive function, mood, and quality of life. Journal of Clinical Oncology 2006;24(9):1415-20.
10. Wellisch DK, Steh B, Kaleita TA, Graham CA, Cloughes TF. A modafinil therapeutic trial for adult brain tumor patients: III. Depression outcomes. Psycho-oncology 2006;15 Suppl:455.
11. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). American Journal of Psychiatry 2000;157 Suppl 4:1-45.
12. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th edition, text rev.). Diagnostic and Statistical Manual of Mental Disorders (4th edition, text revision). Washington DC: American Psychiatric Association, 2000.
13. Armstrong CL, Goldstein B, Cohen B, et al.Clinical predictors of depression in patients with low-grade brain tumors: consideration of a neurologic versus a psychogenic model. Journal of Clinical Psychology in Medical Settings 2002;9(2):97-107.
14. Barnholtz-Sloan JS, Sloan AE, Schwartz AG. Relative survival rates and patterns of diagnosis analyzed by time period for individuals with primary malignant brain tumour, 1973-1997. Journal of Neurosurgery 2003;99(3):458-66.
15. Cassano P, Fava M. Tolerability issues during long-term treatment with antidepressants. Annals of Clinical Psychiatry 2004;16(1):15-25.
16. Dalton SO, Laursen TM, Ross L, Mortensen PB, Johansen C. Risk for hospitalisation with depression after a cancer diagnosis: a nationwide, population-based study of cancer patients in Denmark from 1973 to 2003. Journal of Clinical Oncology 2009;27:1440-5.
17. Feuerstein M, Hansen JA, Calvio LC, Johnson L, Ronquillo JG. Work productivity in brain tumor survivors. Journal of Occupational and Environmental Medicine 2007;49:803-11.
18. First MB, Spitzer RL, Gibbon M. Structured Clinical Interview for DSM-IV-TR Axis I disorders. Patient Edition (SCID-I/P, 11/2002 revision) 2002.
19. Gathinji M, McGirt M, Attenello F, Chaichana K, Than K, Olivi A, et al.Association of preoperative depression and survival after resection of malignant brain astrocytoma. Surgical Neurology 2009;71(3):299-303.
20. Gelder M (editor). Oxford Textbook of Psychiatry. Oxford University Press, 2000.
21. Greenberg DB. Barriers to the treatment of depression in cancer patients. Journal of the National Cancer Institute. Monographs 2004;32:127-35.
22. Hachad H, Ragueneau-Majlessi I, Levy RH. New antiepileptic drugs: review on drug interactions. Therapeutic Drug Monitoring 2002;24(1):91-103.
23. Hackett ML, Anderson CS, House AO, Xia J. Interventions for treating depression after stroke. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.CD003437.pub3].
24. Hesdorffer DC, Hauser WA, Annegers JF, Cascino G. Major depression is a risk factor for seizures in older adults. Annals of Neurology 2000;47:246-9.
25. Iosifescu DV, Bankier B, Fava M. Impact of medical co-morbid disease on antidepressant treatment of major depressive disorder. Current Psychiatry Reports 2004;6(3):193-201.
26. Lima MS, Moncrieff J, Soares BGO. Drugs versus placebo for dysthymia. Cochrane Database of Systematic Reviews 2005, Issue 2. [DOI: 10.1002/14651858.CD001130].
27. Litofsky NS, Resnick AG. The relationship between depression and brain tumours. Journal of Neuro-oncology 2009 Mar 5 [Epub ahead of print].
28. Louis DN, Ohgaki H, Wiestler OD. The 2007 classification of tumours of the central nervous system. Acta Neuropathologica 2007;114(2):97-109.
29. Mainio A, Hakko H, Timonen M, Niemelä A, Koivukangas J, Räsänen P. Depression in relation to survival among neurosurgical patients with a primary brain tumor: a 5-year follow-up study. Neurosurgery 2005;56:1234-42.
30. Mainio A, Hakko H, Niemela A. Gender difference in relation to depression and quality of life among patients with a primary brain tumour. European Psychiatry: the journal of the Association of European Psychiatrists 2006;21(3):194-9.
31. Mainio A, Tuunanen S, Hakko H. Decreased quality of life and depression as predictors for shorter survival among patients with low-grade gliomas: a follow-up from 1990 to 2003. European Archives of Psychiatry and Clinical Neuroscience 2006;256(8):516-21.
32. Moncrieff J, Wessely S, Hardy R. Active placebos versus antidepressants for depression. Cochrane Database of Systematic Reviews 2004, Issue 1. [DOI: 10.1002/14651858.CD003012.pub2].
33. Montgomery SA. Antidepressants and seizures: emphasis on newer agents and clinical implications. International Journal of Clinical Practice 2005;59(12):1435-40.
34. Mottram P, Wilson K, Strobl J. Antidepressants for depressed elderly. Cochrane Database of Systematic Reviews 2006, Issue 1. [DOI: 10.1002/14651858.CD003491.pub2].
35. Management of depression in primary and secondary care. National Clinical Practice Guideline No. 23. London: National Institute for Health and Care Excellence 2004.
36. Pace A, Bove L, Innocenti P. Epilepsy and gliomas: incidence and treatment in 119 patients. Journal of Experimental and Clinical Cancer Research 1998;17(4):479-82.
37. Pangilinan PH Jr, Kelly BM, Pangilinan JM. Depression in the patient with brain cancer. Community Oncology 2007;4:533-7.
38. Parkin DM, Whelan SL, Ferlay J. Cancer incidence in five continents, vol. I to VIII. IARC Cancerbase No 7, Lyon 2005.
39. Peretti S, Judge R, Hindmarch I. Safety and tolerability considerations: tricyclic antidepressants vs. selective serotonin re-uptake inhibitors (Antidepressant selection: Proceedings from a TCA/SSRI consensus conference). Acta Psychiatrica Scandinavia 2000;101 Suppl 403:17-25.
40. Pignatti F, van den Bent M, Curran D. Prognostic factors for survival in adult patients with cerebral low-grade glioma. Journal of Clinical Oncology 2002;20(8):2076-84.
41. Price TRP, Goetz KL, Lovell MR. Neuropsychiatric aspects of brain tumors. In: Yudofsky SC, Hales RE editor(s). The American Psychiatric Publishing Textbook of Neuropsychiatry and Behavioural Neurosciences. 5th Edition. Arlington: American Psychiatric Publishing Inc., 2008.
42. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
43. Rihmer Z. Suicide risk in mood disorders. Current Opinion in Psychiatry 2007;20:17-22.
44. Rooney AG, McNamara S, MacKinnon M, Fraser M, Rampling R, Carson A, et al.Frequency, clinical associations, and longitudinal course of major depressive disorder in adults with cerebral glioma. Journal of Clinical Oncology 2011;29:4307-12.
45. Sharpe M, Strong V, Allen K. Major depression in outpatients attending a regional cancer centre: screening and unmet treatment needs. British Journal of Cancer 2004;90:314-20.
46. Stefanova E, Potrebic A, Ziropdja L. Depression predicts the pattern of cognitive impairment in early Parkinson's disease. Journal of the Neurological Sciences 2006;248:131-7.
47. Strong V, Waters R, Hibberd C, Rush R, Cargill A, Storey D, et al.Emotional distress in cancer patients: the Edinburgh Cancer Centre symptoms study. British Journal of Cancer 2007;96(6):868-74.
48. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al.Radiotherapy plus concomitant and adjuvant chemotherapy for glioblastoma. New England Journal of Medicine 2005;352:987-96.
49. Van Den Bent MJ, Afra D, de Witte O. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005;366:985-90.
50. Weitzner MA. Psychosocial and neuropsychiatric aspects of patients with primary brain tumors. Cancer Investigation 1999;17(4):285-91.
51. Wellisch DK, Kaleita TA, Freeman D. Predicting major depression in brain tumour patients. Psycho-oncology 2002;11:230-8.
52. Wen PY, Kesari S. Malignant gliomas in adults. New England Journal of Medicine 2008;359:492-507.
53. Wijkstra J, Lijmer J, Balk F, Geddes J, Nolen WA. Pharmacological treatment for psychotic depression. Cochrane Database of Systematic Reviews 2005, Issue 4. [DOI: 10.1002/14651858.CD004044.pub2].
54. Wrensch M, Minn Y, Chew T. Epidemiology of primary brain tumours: current concepts and review of the literature. Neuro-oncology 2002;4:278-99.
55. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatrica Scandinavia 1968;67:361-70.
56. Rooney A, Grant R. Pharmacological treatment of depression in patients with a primary brain tumour. Cochrane Database of Systematic Reviews 2010, Issue 3. [DOI: 10.1002/14651858.CD006932.pub2].